Amgen Inc. ($AMGN) Stock Forecast: Down 5.1% Today

What is Amgen Inc.?

Amgen (NASDAQ: AMGN) is a biotechnology company that focuses on developing innovative therapies to treat serious illnesses. The company is known for its strong pipeline of drugs and consistent financial performance.

Why is Amgen Inc. going down?

AMGN stock is down 5.1% on Aug 6, 2025 18:41

• Despite surpassing earnings and revenue projections in the second quarter, the stock displayed downward movement.
• The market's reaction may be linked to concerns about the company's future growth potential despite the positive outcomes.
• Investors appear to be capitalizing on gains following a period of robust performance, causing a temporary decline in the stock value.
• Various broader market dynamics such as sector shifts or general market sentiment could be influencing Amgen's stock price negatively.

AMGN Price Chart

AMGN Technical Analysis

AMGN News

Why Is Amgen Stock Falling Wednesday? - Amgen ( NASDAQ:AMGN )

Amgen Q2 EPS of $6.02 beats estimates, with 21% YoY growth. Revenue rose 9% to $9.18 billion, driven by 13% volume growth. The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday. Amgen Inc.

https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/08/46917706/amgen-stock-sinks-as-market-eyes-maritides-next-move

Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly

Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.

https://www.zacks.com/stock/news/2673239/amgens-q2-earnings-sales-beat-estimates-2025-view-raised-slightly

Amgen ( AMGN ) Beats Q2 Earnings and Revenue Estimates

Amgen (AMGN) delivered earnings and revenue surprises of +14.45% and +3.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2669533/amgen-amgn-beats-q2-earnings-and-revenue-estimates

Gear Up for Amgen ( AMGN ) Q2 Earnings: Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.

https://www.zacks.com/stock/news/2643512/gear-up-for-amgen-amgn-q2-earnings-wall-street-estimates-for-key-metrics

Trending Today

Amgen Inc. Price History

20.11.2024 - AMGN Stock was up 5.4%

• Despite a slight decrease in the most recent trading session, the overall bullish movement of Amgen's stock indicates strong investor confidence in the company.
• The -0.21% shift may be attributed to minor profit-taking or market fluctuations rather than any significant negative news impacting the company.
• Investors continue to show interest in Amgen due to its robust pipeline of biopharmaceutical products and potential for future growth in the healthcare industry.
• The positive sentiment towards Amgen aligns with the broader market optimism towards biotech companies, driving the stock's bullish movement.

17.03.2025 - AMGN Stock was down 6.3%

• Amgen's stock experienced a bearish movement likely due to the lawsuit filed by Sandoz alleging illegal blocking of biosimilar competition for Enbrel, a significant revenue-generating arthritis drug.
• The legal battle and uncertainty surrounding the availability of Erelzi in the U.S. due to contested patents for Enbrel could have contributed to the negative market sentiment towards Amgen.
• Despite a slight gain in a recent trading session, the overall bearish trend today could be attributed to concerns over potential legal implications and competition affecting Amgen's market position and revenue streams.

05.01.2025 - AMGN Stock was up 5.4%

• The strong bullish movement of Amgen (AMGN) today is attributed to an impressive Q4 earnings report that surpassed expectations in both earnings and sales, indicating the company's strong financial position and growth potential.
• Despite the FDA's decision to place a clinical hold on Amgen's obesity candidate, AMG 513, which initially raised concerns among investors, the overall positive earnings results overshadowed this development.
• The high bullish sentiment among investors, evident from options trading data, further boosted the stock's upward trend, reflecting a positive outlook on Amgen's future.
• Despite the regulatory setback with AMG 513, Amgen's robust performance in Q4 and the optimistic market sentiment suggest that the company is well-positioned for continued growth within the biotech sector.

05.01.2025 - AMGN Stock was up 6.6%

• During Q4, Amgen surpassed revenue and EPS expectations, impressing investors and boosting confidence in the company's growth trajectory.
• While facing a regulatory setback with the FDA's clinical hold on AMG 513 for obesity, Amgen's robust earnings performance outweighed concerns in the market.
• Favorable sentiment from influential investors and optimistic projections from analysts have contributed to Amgen's upward momentum.
• Despite regulatory hurdles, Amgen's financial strength and positive market outlook likely fueled today's significant bullish movement in the stock.

24.05.2025 - AMGN Stock was down 5.8%

• AMGN's stock price closed at $272.44, representing a significant -5.84% decrease compared to the previous day.
• The market response was influenced by the mixed outcomes of Part 1 of its Phase 2 study of MariTide, causing uncertainty among investors and resulting in downward pressure on the stock.
• Options trading activities indicate a prevailing bearish sentiment, with a majority of traders leaning towards pessimistic positions, exacerbating the selling pressure on AMGN's shares.
• Despite the current downward trend, some investors may view the decline in AMGN's stock price as an opportunity to potentially profit from the company's history of developing cutting-edge therapies in the long run.

05.01.2025 - AMGN Stock was up 5.1%

• Amgen (AMGN) experienced a strong bullish movement.
• The positive sentiment may stem from expectations of surpassing Q4 earnings estimates.
• Investors are optimistic about Amgen's performance for the quarter ending December 2024, contributing to the bullish trend.
• The market movement indicates faith in Amgen's potential to deliver robust financial outcomes, sparking investor enthusiasm for the stock.

09.03.2025 - AMGN Stock was down 5.7%

• The approval of Amgen's Uplizna for new rare autoimmune disease indications by the FDA was positive news for the company.
• Despite the positive developments with Uplizna, the stock saw a bearish trend, possibly due to profit-taking after recent spikes in the past year.
• The market's overall volatility and uncertainty may have contributed to the stock's decline despite the positive news.
• Investors might be cautious about the company's future performance, leading to a sell-off despite the overall market taking a dip.

02.06.2025 - AMGN Stock was up 5.2%

• Bemarituzumab, Amgen's gastric cancer drug, demonstrated enhanced survival rates in Phase 3 trials for advanced gastric cancer patients, likely bolstering investor trust in the company's pipeline and future revenue opportunities.
• The progress of MariTide, a monthly treatment for obesity in late-stage trials, signals Amgen's strategic move into the obesity market, attracting investor attention and optimism.
• The commencement of a Phase 3 study by VKTX on an obesity candidate might suggest growing competition in the obesity treatment sector, yet Amgen's established reputation and robust pipeline could help it maintain a competitive position.
• The prevailing positive market sentiment and Amgen's +1.03% stock price rise may indicate investor confidence in the company's innovative drug pipeline and its potential for future expansion and growth.

06.07.2025 - AMGN Stock was down 5.1%

• Despite surpassing earnings and revenue projections in the second quarter, the stock displayed downward movement.
• The market's reaction may be linked to concerns about the company's future growth potential despite the positive outcomes.
• Investors appear to be capitalizing on gains following a period of robust performance, causing a temporary decline in the stock value.
• Various broader market dynamics such as sector shifts or general market sentiment could be influencing Amgen's stock price negatively.

06.07.2025 - AMGN Stock was down 5.2%

• Despite surpassing Q2 earnings and revenue projections, Amgen (AMGN) faced a downturn in the market today.
• The market's reaction could be attributed to concerns regarding the company's future growth trajectory or provided guidance.
• Investors may have had higher expectations, prompting profit-taking and a temporary decline in the stock value.
• It is crucial to observe how Amgen addresses any potential underlying issues to determine the continuity of this bearish trend or whether it signals a buying opportunity for investors.

04.03.2025 - AMGN Stock was down 5.0%

• The FDA approval of Uplizna as the first drug for a chronic immune-mediated fibroinflammatory disorder should have been a positive catalyst for Amgen, but the bearish movement suggests otherwise.
• Despite positive clinical data and market resilience, the stock experienced a significant plunge, possibly due to profit-taking or broader market uncertainties.
• The bearish sentiment from deep-pocketed investors, as indicated by options trading, might have contributed to the downward pressure on Amgen's stock price.
• The mixed signals from the market, including a recent rise amidst a general market dip and a slight decrease in P/E ratio, could have added to the overall confusion and led to the bearish movement in AMGN today.

23.05.2025 - AMGN Stock was down 5.4%

• Today's bearish movement in AMGN may have been driven by market sentiment reflected through options trading, where a majority of traders displayed bearish tendencies.
• Noteworthy bearish actions by financial giants on Amgen might have caused apprehension among investors, prompting a sell-off of the stock.
• The analysis of options history revealing a higher percentage of bearish trades could have intensified the negative sentiment surrounding Amgen and contributed to today's significant bearish movement in the stock.